Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to “Qnovia,” the company said. No reason for the name change was announced, but the previous name was similar to that of Respira Therapeutics, which is developing a vardenafil DPI for the treatment of pulmonary arterial hypertension (PAH).
Qnovia says that it is planning an IND submission and is seeking financing for clinical trials of a smoking cessation product based on its RespiRx breath-activated, metered dose, handheld vibrating mesh nebulizer. The Qnovia web site describes its RespiRx product as “an easy to use, zero-maintenance cartridge-based medical grade inhaled drug delivery system that will be prescribed by a doctor to help smokers finally quit smoking.”
Read the Qnovia press release.
